Summary Objectives: To examine the safety and efficacy of ombitasvir and ABT-450 with ritonavir (ABT-450/r) AE ribavirin (RBV) in treatment-na€ ıve, non-cirrhotic adults with chronic HCV genotype 1e3 infection. Methods: Patients in this open-label, exploratory, phase 2, multicenter study received ombitasvir (25 mg QD) and ABT-450/r (200/100 mg QD) AE RBV for 12 weeks. Primary efficacy endpoint was HCV RNA < lower limit of quantitation (LLOQ) from week 4 through 12. Sustained virologic response 12 weeks post-treatment (SVR 12 ) was a secondary endpoint. Results: Sixty-one patients were enrolled. Among genotype 1-, 2-, and 3-infected patients, respectively, HCV RNA was<LLOQ from week 4 through 12 in 10 (100%; 95% CI 69e100), 9 (90%; 56e100), and 7 (70%; 35e93) receiving the RBV-containing regimen and 9 (90%; 56 e100), 8 (80%; 44e97), and 2 (18%; 2e52) receiving the RBV-free regimen. Among genotype 1-, 2-, and 3-infected patients, respectively, SVR 12 was achieved by 10 (100%), 8 (80%), and 5 (50%) receiving the RBV-containing regimen, and 6 (60%), 6 (60%), and 1 (9%) receiving the * Corresponding author. Tel.: þ1 210 253 3426; fax: þ1 210 477 1808.
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Introduction
It is estimated that 150 million people worldwide have chronic hepatitis C virus (HCV) infection.
1 HCV-related cirrhosis is a leading indication for liver transplantation and a contributor to the increasing incidence of hepatocellular carcinoma. 2 HCV is currently classified into 7 different genotypes. 3 HCV genotypes 1, 2, and 3 have a wide global distribution. 4 HCV genotype 1 is the most common worldwide with subgenotype varying by geographic region. Subgenotype 1a predominates in North America and some countries in Western Europe, while subgenotype 1b predominates in Southern and Eastern Europe, Latin America, and Asia.
4e6 HCV genotypes 2 and 3 are common in Latin America, Europe, and Asia, with rates varying by country. 6e8 HCV genotypes 2 and 3 represent 16% and 12%, respectively, of HCV infections in the United States. 9, 10 Historically, therapies for HCV genotype 1, 2, and 3 infection have been peginterferon (pegIFN)-based. PegIFN is associated with adverse events including influenza-like symptoms and depression. Many patients decline pegIFN therapy, and a substantial number of patients with HCV infection have contraindications for pegIFN-based therapy due to co-existing medical conditions.
The former standard of care for treatment of HCV genotype 1 infection was pegIFN and ribavirin (RBV) with either telaprevir or boceprevir administered for up to 48 weeks, which resulted in sustained virologic response (SVR) rates of 66%e75% in treatment-na€ ıve patients. 11, 12 The current standard of care is 12 weeks of the NS5B polymerase inhibitor sofosbuvir administered with pegIFN/RBV or 12 weeks of the protease inhibitor simeprevir with 24 weeks of pegIFN/ RBV. These therapies achieve SVR rates of 80%e90%. 13, 14 Recent phase 3 trials have shown encouraging results for pegIFN-free regimens in genotype 1-infected patients. For genotype 2-or 3-infected patients, pegIFN/RBV for up to 24 weeks was formerly the standard of care. This resulted in SVR rates of 54%e78% in treatment-na€ ıve genotype 2-infected patients and 64%e66% in treatmentna€ ıve genotype 3-infected patients. 22e24 An SVR rate of 93% has been reported among genotype 2-infected patients receiving 12 weeks of sofosbuvir plus RBV, and an SVR rate of 85% has been reported among genotype 3-infected patients receiving 24 weeks of sofosbuvir plus RBV. 25 Ombitasvir (ABT-267) is an HCV NS5A inhibitor dosed once daily. 26, 27 ABT-450 is an HCV NS3/4A protease inhibitor, identified by AbbVie and Enanta as a lead compound for clinical development. ABT-450 is co-dosed with low-dose ritonavir, a CYP3A4 inhibitor, to achieve therapeutic exposures at lower doses and at once daily dosing frequency (the combination is denoted ABT-450/r). 27 Ombitasvir has picomolar potency and ABT-450 has nanomolar potency against HCV genotypes 1, 2, and 3 in vitro. Phase 2 and 3 studies have demonstrated high SVR rates and tolerability of combination regimens that include ABT-450/r and ombitasvir with or without ribavirin in genotype 1-infected patients. 17,18,21,28e31 In this exploratory phase 2 study, we assessed the safety and efficacy of pegIFN-free regimens of ombitasvir and ABT-450/r with or without RBV in treatmentna€ ıve adults with chronic HCV genotype 1, 2, or 3 infection.
Patients and methods

Study design and participants
This was an open-label, sequential arm, multicenter, combination treatment phase 2 study. Patients were screened and enrolled at 15 sites in the United States from September 2011 to March 2012. Treatment-na€ ıve adults age 18e65 years (inclusive) with a BMI !18 and <35 kg/m 2 and general good health, who were chronically infected with HCV genotype 1, 2, or 3 without evidence of cirrhosis, were eligible. Absence of cirrhosis was based on documented results of a FibroTest score of 0.72 and Aspartate Aminotransferase to Platelet Ratio 2, or Fibroscan result of <9.6 kPa at screening, or a liver biopsy within the last 36 months. Cohorts enrolling HCV genotype 1-infected patients were required to include at least 5 patients with HCV subgenotype 1a infection and at least 2 patients with HCV subgenotype 1b infection. Cohorts enrolling HCV genotype 2-infected patients were required to include at least 2 patients with HCV subgenotype 2a infection and at least 5 patients with HCV subgenotype 2b infection. Patients were excluded if they had HIV or hepatitis B co-infection, or if they previously used any investigational or commercially available anti-HCV agents.
The study was performed in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki, and was approved by the relevant institutional review boards and regulatory agencies. All patients provided written informed consent.
Procedures
Eligible patients received either ombitasvir and ABT-450/r with RBV (Arm 1) or ombitasvir and ABT-450/r without RBV (Arm 2) for 12 weeks. Each arm included a cohort of genotype 1-infected patients, a cohort of genotype 2-infected patients, and a cohort of genotype 3-infected patients. Arms were enrolled sequentially. Once a cohort within Arm 1 was fully enrolled, the cohort of the same genotype in Arm 2 began enrolling patients. Patients received ombitasvir 25 mg once daily and ABT-450/r 200/100 mg once daily. RBV dosing was weight-based (1000 mg or 1200 mg total daily divided into 2 daily doses).
HCV genotype and subgenotype were assessed from screening-visit blood samples using the Versant Ò HCV Genotype Inno-LiPA Assay, version 2.0 or higher (LiPA; Siemens Healthcare Diagnostics, Tarrytown, NY). Because of the known limitations with this assay's ability to determine subgenotypes for genotypes 2 and 3, an additional analysis was conducted on some samples from genotypes 2 and 3 infected patients. The NS3 and NS5A genes were amplified by reverse transcription-PCR (RT-PCR) from viral RNA using subgenotype-specific primers. These PCR products were sequenced by a third party vendor, and the genotypes of the resulting nucleotide sequences were determined by Basic Local Alignment Search Tool analysis against sequences in GenBank. In addition, the NS5A gene amplified from baseline samples from all genotype 2-and 3-infected patients was used to perform a phylogenetic analysis (maximum-likelihood tree with 100 bootstrapping replicates) in order to confirm the subgenotype of virus in each sample.
Blood samples for assessing plasma HCV RNA levels were collected at the screening-visit, prior to dosing on study day 1, day 3, weekly through week 12, and at post-treatment weeks 2, 4, 8, 12, 24, 36, and 48, or upon patient discontinuation. A central laboratory assessed plasma HCV RNA levels for each sample collected using the Roche COBAS TaqMan Ò real-time reverse transcriptase-PCR (RT-PCR) assay, which has a lower limit of detection (LLOD) of 15 IU/mL and a lower limit of quantitation (LLOQ) of 25 IU/mL.
Virologic stopping criteria were: (a) failure to achieve 2 log 10 IU/mL HCV RNA decrease at week 1; (b) confirmed increase from nadir in HCV RNA >1 log 10 IU/mL at any time point; (c) failure to achieve HCV RNA < LLOQ at week 6; or (d) confirmed HCV RNA > LLOQ (defined as 2 consecutive HCV RNA measurements > LLOQ) at any point after HCV RNA < LLOQ. Virologic breakthrough during treatment was defined as confirmed increase of at least 1 log 10 IU/mL above nadir or confirmed HCV RNA > LLOQ for patients who previously achieved HCV RNA < LLOQ during treatment. Relapse was defined as confirmed HCV RNA > LLOQ post-treatment for patients with HCV RNA < LLOQ at the end of treatment.
For resistance-associated variant testing, viral RNA was extracted from plasma samples collected at baseline and after treatment failure. The target gene was amplified from HCV viral RNA by RT-PCR using subgenotype-specific primers for NS3/4A or NS5A. The PCR product was used as the template for DNA sequencing which was performed by a third party, Good Laboratory Practice (GLP)-certified laboratory. In addition, the NS5A PCR product or a secondary PCR product containing the protease catalytic domain generated from the larger NS3/4A RT-PCR product was inserted into a DNA plasmid vector, transformed into an Escherichia coli host, and plasmid DNA from individual bacterial clones was purified. The inserted NS3 protease or NS5A gene was sequenced from 47 to 97 clones per sample (average Z 82).
Safety and tolerability assessment occurred at all study visits and included physical examinations, clinical laboratory tests, twelve-lead electrocardiography, and vital signs. Number and percentage of patients reporting treatmentemergent adverse events were tabulated by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class and preferred term. Tabulations of treatmentemergent adverse events were also provided by severity rating and relationship to study drug. All adverse events reported from the time of study drug administration until 30 days following discontinuation of study drug administration were collected. Serious adverse events were collected from the time the patients signed the informed consent through the 48-week post-treatment period.
Statistical analysis
The primary endpoint in this exploratory study was the percentage of patients with HCV RNA suppressed below LLOQ from week 4 through week 12. Secondary endpoints included percentage of patients with sustained virologic response (HCV RNA < LLOQ) at 12 weeks post-treatment (SVR 12 ) and percentage of patients with sustained virologic response at 24 weeks post-treatment (SVR 24 ). Demographic, safety, and efficacy analyses were performed on all patients who received at least one dose of study drug. All statistical tests and confidence intervals were 2-sided with an a level of 0.05. SAS for the UNIX operating system was used for all analyses. For analysis of adverse events, Arms 1 and 2 were compared using Fisher's exact test.
This study is registered with ClinicalTrials.gov, number NCT01458535.
Results
One hundred forty patients were screened and 61 patients were enrolled in the study. Commonly occurring reasons for exclusion included: (a) an abnormal laboratory result at screening, (b) an exclusionary FibroTest score or Aspartate Aminotransferase to Platelet Ratio, and (c) the appropriate cohort for the study patient was already fully enrolled. All enrolled patients received at least 1 dose of study drug (Fig. 1) . Baseline characteristics were generally wellbalanced between cohorts of the same genotype (Table 1 ). Phylogenetic analysis indicated that the HCV subgenotype designation for all patients was accurate (Supplemental Fig. 1 ).
Efficacy
On-treatment and post-treatment virology results for each individual patient are shown in Supplemental Fig. 2 . Virologic response rates are presented in Table 2 . Among patients in Arm 1 (ombitasvir and ABT-450/r with RBV) HCV RNA was suppressed below LLOQ from week 4 through 12 in 10 (100%; 95% CI, 69e100) HCV genotype 1-infected patients, 9 (90%; 95% CI, 56e100) HCV genotype 2-infected patients, and 7 (70%; 95% CI, 35e93) HCV genotype 3-infected patients. Among patients in Arm 2 (ombitasvir and ABT-450/r without RBV) HCV RNA was suppressed below LLOQ from week 4 through 12 in 9 (90%; 95% CI, 56e100) HCV genotype 1-infected patients, 8 (80%; 95% CI, 44e97) HCV genotype 2-infected patients, and 2 (18%; 95% CI, 2e52) HCV genotype 3-infected patients. The rate of HCV RNA suppression below LLOQ from week 4 through 12 was greater with the RBV-containing regimen than the RBV-free regimen overall (Arm 1 vs. Arm 2, P Z 0.037) and in HCV genotype 3-infected patients (Cohort 3 vs. Cohort 6, P Z 0.037) ( Table 3) . SVR 12 was achieved by 10 (100%; 95% CI 69e100) HCV genotype 1-infected patients, 8 (80%; 95% CI, 44e97) HCV genotype 2-infected patients, and 5 (50%; 95% CI, 19e81) HCV genotype 3-infected patients receiving the RBV-containing regimen. All of these patients went on to achieve SVR 24 , except for 1 HCV genotype 3-infected patient who relapsed at post-treatment week 24. Phylogenetic analysis indicates that this was likely a new infection with HCV subgenotype 2b. The resulting SVR 24 rate was 40% (95% CI, 12e74) in HCV genotype 3-infected patients receiving the RBVcontaining regimen. SVR 12 was achieved by 6 (60%; 95% CI, 26e88) HCV genotype 1-infected patients, 6 (60%; 95% CI, 26e88) HCV genotype 2-infected patients, and 1 (9%; 95% CI, 0e41) HCV genotype 3-infected patient receiving the RBV-free regimen. All of these patients achieved SVR 24 . SVR 12 rates were greater with the RBV-containing regimen compared to the RBV-free regimen overall (Arm 1 Figure 1 Study profile. Thirty patients with HCV genotype 1-3 received at least one dose of ombitasvir and ABT-450/r with ribavirin. Thirty-one patients with HCV genotype 1e3 received at least one dose of ombitasvir and ABT-450/r without ribavirin. vs. Arm 2, P Z 0.005), in HCV genotype 1-infected patients (Cohort 1 vs. Cohort 4, P Z 0.037), and in HCV genotype 3-infected patients (Cohort 3 vs. Cohort 6, P Z 0.046) ( Table 3 ). SVR 24 rates with the RBV-containing regimen compared to the RBV-free regimen were greater overall (Arm 1 vs. Arm 2, P Z 0.008) and in HCV genotype 1-infected patients (Cohort 1 vs. Cohort 4, P Z 0.037). Among patients receiving the RBV-containing regimen, no HCV genotype 1-infected patient experienced virologic failure, 1 HCV genotype 2-infected patient experienced breakthrough, and there were 3 breakthroughs and 2 relapses in HCV genotype 3-infected patients. Among patients receiving the RBV-free regimen, there was 1 breakthrough and 2 relapses in a genotype 1-infected patient, and 1 breakthrough and 2 relapses in genotype 2-infected patients; there were 8 breakthroughs and 1 relapse in genotype 3-infected patients. All three HCV genotype 1-infected patients experiencing virologic failure had subgenotype 1a. All four HCV genotype 2-infected patients experiencing virologic failure had subgenotype 2b. Two patients who relapsed (1 HCV genotype 2-infected patient and 1 HCV genotype 3-infected patient receiving the RBV-free regimen) took less than 40% of their prescribed doses of each study drug.
Of the 4 patients with baseline resistance-associated variants in NS5A, 1 subgenotype 1a-infected patient and 1 subgenotype 2a-infected patient achieved SVR 12 and SVR 24 , 1 subgenotype 1a-infected patient experienced breakthrough, and 1 subgenotype 1a-infected patient relapsed. Two subgenotype 3a-infected patients had baseline resistance-associated variants in NS3 protease; both experienced breakthrough. The 4 patients with a baseline resistance-associated variant who experienced virologic failure had 2-class resistance at the time of failure. Additional data on resistance-associated variants at baseline and at time of virologic failure are in the Supplemental Table.
Safety
The most common treatment-emergent adverse events were fatigue, nausea, and headache (Table 4 ). The majority of treatment-emergent adverse events were mild or moderate. Three patients had treatment-emergent serious adverse events (meningitis herpes; arteriosclerosis; and road traffic accident, with traumatic liver injury, facial bones fracture, rib fracture, and lumbar vertebral fracture). Each of these events was deemed not related to study drug by the investigators. One serious adverse event (meningitis herpes) led to discontinuation of study drug. This was the only discontinuation due to an adverse event.
The patient with the serious adverse event of arteriosclerosis died 8 days post-treatment. Autopsy revealed myocardial hypertrophy, arteriolonephrosclerosis and cardiac arteriosclerosis, hyalination/mineralization of central arterioles, left anterior descending coronary artery stenosis, and myocardial fibrosis. This event was considered not related to study drugs by the investigator.
Treatment-emergent grade 3e4 laboratory abnormalities were infrequent (Table 5) . One patient had a grade 4 ALT elevation concurrent with a grade 3 AST elevation. These elevations coincided with use of hormonal contraceptives. One Table 2 Virologic response rates. patient had a grade 3 elevation in ALT without a concomitant grade 3e4 elevation in AST; this patient subsequently discontinued prematurely due to virologic failure. In both patients, these elevations were asymptomatic and neither patient had a concomitant grade 3e4 elevation in total bilirubin. Four of the nine grade 3e4 laboratory abnormalities occurred at a single visit. The one documented grade 3 elevation of bilirubin was mainly indirect. There were no grade 3e4 reductions in hemoglobin, and no patient received a transfusion. All grade 3e4 laboratory abnormalities resolved on treatment or shortly thereafter. There were no discontinuations due to laboratory abnormalities.
Discussion
In this exploratory study of pegIFN-free regimens of ombitasvir and ABT-450/r with or without RBV in treatment-na€ ıve, non-cirrhotic patients with HCV genotype 1, 2, or 3 infection, rapid suppression of HCV RNA was observed in the majority of patients receiving the RBV-containing regimen, regardless of patient genotype. Among patients receiving the RBV-free regimen, most HCV genotype 1-and 2-infected patients demonstrated HCV RNA suppressed below LLOQ from week 4 through 12; however, few patients with HCV genotype 3 infection achieved this endpoint. The RBV-containing regimen resulted in high SVR 12 rates, while the SVR 12 rates observed in patients receiving the RBV-free regimen were lower. All patients who achieved SVR 12 in this study went on to achieve SVR 24 , except 1 HCV genotype 3-infected patient whose relapse was likely a new infection, based on phylogenetic analysis. In the current study, response rates were high in patients with HCV genotype 1 infection who received either the RBV-containing or the RBV-free regimen. It is important to note that 80% of the HCV genotype 1-infected patients in this study had subgenotype 1a, which has reportedly been more difficult to treat than subgenotype 1b when using protease inhibitor-based direct-acting antiviral regimens. 32e34 Combination regimens that include ombitasvir and ABT-450/r with or without RBV have been studied in genotype 1-infected patients in other phase 2 and phase 3 studies. In a phase 2b trial evaluating various combinations 29 A phase 2 study assessing a 12-week regimen of ABT-450/r and ombitasvir without RBV in genotype 1b-infected patients reported SVR 12 rates of 95.2% in treatment-na€ ıve patients and 90.0% in prior pegIFN/RBV-null responder patients. 30 In phase 3 trials, a regimen of ombitasvir/ABT-450/r and dasabuvir with RBV was evaluated in treatment-na€ ıve and pegIFN/RBV treatment-experienced HCV genotype 1-infected patients with and without cirrhosis. Regimens of ombitasvir/ABT-450/r and dasabuvir with RBV achieved SVR 12 rates up to 96% in each of the large patient populations evaluated in these trials. 17, 21, 31 Other phase 3 trials evaluated this regimen with and without RBV. 18 SVR 12 rates of 97.0% and 90.2% were observed in HCV subgenotype 1a-infected patients receiving ombitasvir/ABT-450/ r and dasabuvir with and without RBV, respectively.
18 SVR 12 rates in HCV subgenotype 1b-infected patients receiving ombitasvir/ABT-450/r and dasabuvir with and without RBV were 99.0% and 99.5%, respectively. 18 Response rates in this study in HCV genotype 2-infected patients were high despite 80% of the patients having subgenotype 2b infection, which has been identified as more difficult to treat with pegIFN-containing regimens than subgenotype 2a. 22, 35, 36 The exploratory regimens in this study resulted in SVR in some HCV genotype 3-infected patients, but the overall SVR rates in this group of patients were low.
The results of this study also indicate that the safety and tolerability of both the RBV-containing and RBV-free regimen compare favorably to pegIFN-based therapy. Patients receiving these all-oral regimens avoid the subcutaneous injections required for pegIFN therapy. Also, the rates of adverse events commonly associated with pegIFN treatment, such as fatigue, headache, nausea, and depression, were lower in patients in this study than previously reported in patients receiving pegIFN. 37 One patient in this study had a grade 3 bilirubin elevation; this elevation was predominantly indirect bilirubin, consistent with the known effect of protease inhibitors on the organic aniontransporting polypeptide 1B1. 38, 39 Overall, the regimens under investigation were generally well-tolerated by patients in this study. Many patients who have contraindications for pegIFN therapy due to comorbidities may be eligible for this pegIFN-free therapy.
This study is limited by the small sample size for each of the 3 genotypes under investigation. The small size limits the ability to determine the impact of baseline characteristics on response. In addition, patients with cirrhosis, who have lower response rates to pegIFN/RBV therapy, were not included in this study. 40 Arms were enrolled sequentially in this small exploratory study. This design may result in some imbalance in baseline and disease characteristics between arms.
In summary, this exploratory study characterized the safety and antiviral activity of ombitasvir and ABT-450/r with or without RBV in patients with HCV genotypes 1, 2, or 3 infection. The regimens were generally well-tolerated and SVR was achieved in most patients with HCV genotype 1 or 2 infection, but low SVR rates were observed in HCV genotype 3-infected patients. While regimens including an additional direct-acting antiviral agent may be needed to maximize SVR rates across patient populations with negative predictors of response, the results of this study support the continued exploration of this 2 direct-acting antiviral regimen.
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